海翔藥業(002099.SZ):擬出資1億元參設合夥企業 以投資復宏漢霖
格隆匯6月4日丨海翔藥業(002099.SZ)公佈,公司與華旗基金管理(台州)有限公司(“華旗基金”)、杭州中大源新股權投資有限公司(“中大源新”)、浙江中大集團投資有限公司(“中大集團”)、虞偉獻、陳方荷、徐寶春共同發起設立了台州富宏股權合夥企業(有限合夥),該合夥企業擬專項投資上海復宏漢霖生物技術股份有限公司。該合夥企業的募集規模為1.56億元,其中公司作為有限合夥人以自有資金認繳1億元出資,佔合夥企業認繳出資的64.10%。
此次投資旨在提高公司資金的使用效率和資本收益水平,提升資產運行質量,藉助相關投資探索與領先生物類似藥企業在業務層面的潛在合作,提升公司產業經營和資本經營的結合能力,提升公司綜合競爭實力和盈利能力,符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.